CREB3 targets for neurodegenerative diseases (G10488)

Target Name: CREB3

NCBI ID: G10488

CREB3

CREB3 targets for neurodegenerative diseases

CREB3 (CREB3_HUMAN) is a protein that is expressed in the brain and is involved in the regulation of a wide range of cellular processes. It is a key player in the CREB/PBD complex, which is a protein-protein interaction network that is involved in memory and learning.

Research has identified several potential drug targets for CREB3, including inhibitors of the CREB3-PDZ domain, which is a protein-protein interaction region of the CREB3 protein that is involved in regulation of the activity of other proteins. Additionally, studies have shown that CREB3 is involved in the regulation of neuronal excitability, which is important for the function of the brain.

One potential drug target for CREB3 is the use of small molecules that can inhibit the activity of CREB3 and disrupt its interaction with other proteins. This approach has been used to develop drugs for a variety of neurological disorders, including Alzheimer's disease and Parkinson's disease.

Another approach to targeting CREB3 is the use of antibodies that can specifically recognize and target the CREB3 protein. This approach has been used to develop drugs for a variety of neurological disorders, including multiple sclerosis and amyotrophic lateral sclerosis.

CREB3 is also being targeted by researchers as a potential biomarker for the diagnosis and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This is because the loss of CREB3 protein is often associated with the development of these conditions, and may be an indicator of the severity of the disease.

In conclusion, CREB3 is a protein that is involved in a wide range of cellular processes and is a potential drug target for a variety of neurological disorders. The use of small molecules and antibodies to target CREB3 and disrupt its interaction with other proteins is an promising approach for the development of new drugs for these disorders. Additionally, CREB3 may also be a useful biomarker for the diagnosis and progression of neurodegenerative diseases.

Protein Name: CAMP Responsive Element Binding Protein 3

Functions: Endoplasmic reticulum (ER)-bound sequence-specific transcription factor that directly binds DNA and activates transcription (PubMed:9271389, PubMed:19779205, PubMed:10984507, PubMed:15845366, PubMed:16940180). Plays a role in the unfolded protein response (UPR), promoting cell survival versus ER stress-induced apoptotic cell death (PubMed:15845366, PubMed:16940180). Also involved in cell proliferation, migration and differentiation, tumor suppression and inflammatory gene expression. Acts as a positive regulator of LKN-1/CCL15-induced chemotaxis signaling of leukocyte cell migration (PubMed:19779205, PubMed:15001559, PubMed:17296613). Associates with chromatin to the HERPUD1 promoter (PubMed:16940180). Also induces transcriptional activation of chemokine receptors (PubMed:18587271, PubMed:17296613)

The "CREB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CREB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets